Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26751201 | 0.86 | TGFBR1 (0.36) | TGFBR1PIK3CDMAP4K4MAPK1MET | |
| SCHEMBL25335507 | 0.86 | MAPK1 (0.36) | TGFBR1PIK3CDMAP4K4MAPK1MET | |
| Hydrochloric Acid SCHEMBL31123021 | 0.84 | TGFBR1 (0.35) | TGFBR1PIK3CDMAP4K4MAPK1MET | |
| SCHEMBL23691885 | 0.83 | TGFBR1 (0.34) | TGFBR1PIK3CDMAP4K4MAPK1MET | |
| SCHEMBL25529726 | 0.83 | TGFBR1 (0.37) | TGFBR1PIK3CDMAP4K4MAPK1MET | |
| SCHEMBL24726642 | 0.82 | MAPK1 (0.41) | TGFBR1PIK3CDMAPK1TNIKPDPK1 | |
| SCHEMBL24167686 | 0.82 | DYRK1A (0.33) | TGFBR1PIK3CDMAP4K4MAPK1MET | |
| SCHEMBL25574192 | 0.82 | TGFBR1 (0.36) | TGFBR1PIK3CDMAP4K4MAPK1MET | |
| SCHEMBL25573467 | 0.81 | TGFBR1 (0.38) | TGFBR1PIK3CDMAP4K4MAPK1MET | |
| SCHEMBL26777270 | 0.80 | TGFBR1 (0.36) | TGFBR1PIK3CDMAP4K4MAPK1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151833-A1 | SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF | CEREVEL THERAPEUTICS, LLC (US) | 2024-07-18 | — | — | WO | disclosed |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240228491-A1 | METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240228491-A1 | METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-12030878-B2 | Substituted indole ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240067638-A1 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067638-A1 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2024-02-29 | — | — | US | disclosed |
| US-11912703-B2 | 6-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912703-B2 | 6-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20170273965-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170273965-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170252317-A1 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA, INC. | 2017-09-07 | — | — | US | disclosed |
| US-9693989-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9693989-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160304516-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. | 2016-10-20 | — | — | US | disclosed |
| US-8648087-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20140023643-A1 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| WO-2012044567-A2 | IMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20110034689-A1 | N4-Phenyl-Quinazoline-4-Amine Derivatives and Related Compounds as ErbB Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases | ARRAY BIOPHARMA, INC. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | EGFR, ERBB2, ERBB3 | TGFBR1 1965/4885PIK3CD 269/4885MAP4K4 1774/4885 |
| US-20140023643-A1 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ERBB4, ERBB2, ERBB3 | TGFBR1 900/4885PIK3CD 426/4885MAP4K4 142/4885 |
| US-20170273965-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | DGAT2, DGAT1, MOGAT2 | TGFBR1 4512/4885PIK3CD 2171/4885MAP4K4 2263/4885 |
| US-20110034689-A1 | N4-Phenyl-Quinazoline-4-Amine Derivatives and Related Compounds as ErbB Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases | ERBB4, ERBB2, ERBB3 | TGFBR1 900/4885PIK3CD 426/4885MAP4K4 142/4885 |
| US-11912703-B2 | 6-azaindole compounds | TLR7, TLR9, TLR5 | TGFBR1 631/4885PIK3CD 1390/4885MAP4K4 2454/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | TGFBR1 4022/4885PIK3CD 2012/4885MAP4K4 145/4885 |
| US-20170252317-A1 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ERBB4, ERBB2, ERBB3 | TGFBR1 900/4885PIK3CD 426/4885MAP4K4 142/4885 |
| US-20240228491-A1 | METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | MAT1A, AMD1, MAT2B | TGFBR1 1950/4885PIK3CD 3931/4885MAP4K4 4436/4885 |
| US-20240067638-A1 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | TLR9, TLR1, TLR7 | TGFBR1 42/4885PIK3CD 797/4885MAP4K4 767/4885 |
| US-20160304516-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | TGFBR1 1855/4885PIK3CD 2148/4885MAP4K4 2764/4885 |
| US-12030878-B2 | Substituted indole ether compounds | TLR7, TLR8, TLR1 | TGFBR1 908/4885PIK3CD 2117/4885MAP4K4 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.